The European Medicines Agency gave a positive opinion regarding the launch of a chikungunya vaccine from the French company Valneva, which was previously approved on November 10 by health authorities in the United States, according to a press release issued by the producer on Monday.
After studying the file on an urgent basis, that is, in 150 days instead of 210, the agency granted “technical approval for the license application to sell the proposed single-dose vaccine from Valneva against chikungunya VLA 1553,” which was approved for sale in the United States under the name “Excheek.”
The statement pointed out that “there is no preventive vaccine or effective treatment for chikungunya in Europe, which therefore makes it a major threat to public health.”
Valneva explained that the vaccine “is prescribed to prevent the disease caused by the chikungunya virus in people aged 18 years and over who are at increased risk of exposure” to the virus.
Chikungunya, which is transmitted by the Aedes mosquito, has spread to more than 110 countries. It is found mainly in tropical regions, especially in Africa, Southeast Asia, and some regions of North and South America.
2023-11-27 22:24:20
#European #Medicines #Agency #approves #launch #French #company #Valneva #vaccine #chikungunya #virus
